Gritstone bio Inc. [NASDAQ: GRTS] loss -42.41% or -5.17 points to close at $7.02 with a heavy trading volume of 17243913 shares. The company report on January 4, 2022 that Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19.
— Single 10 µg dose of samRNA vaccine containing Spike plus additional T cell epitopes (TCE) induced robust neutralizing antibody titers in ten healthy adults ≥60yrs who had received two prior doses of AstraZeneca’s COVID-19 vaccine –.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
— samRNA vaccine elicited broad CD8+ T cell responses against conserved non-Spike SARS-CoV-2 epitopes and boosted pre-existing Spike-specific T cells –.
It opened the trading session at $12.00, the shares rose to $12.0999 and dropped to $6.96, the range by which the price of stock traded the whole day. The daily chart for GRTS points out that the company has recorded -12.14% loss over the past six months. However, it is still -83.77% lower than its most recent low trading price.
If we look at the average trading volume of 1.34M shares, GRTS reached to a volume of 17243913 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Gritstone bio Inc. [GRTS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GRTS shares is $19.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GRTS stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Gritstone bio Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on December 15, 2021. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on October 15, 2021, representing the official price target for Gritstone bio Inc. stock. Previously, the target price had yet another raise to $8, while Robert W. Baird analysts kept a Underperform rating on GRTS stock.
The Average True Range (ATR) for Gritstone bio Inc. is set at 1.44, with the Price to Sales ratio for GRTS stock in the period of the last 12 months amounting to 10.37. The Price to Book ratio for the last quarter was 2.63, with the Price to Cash per share for the same quarter was set at 2.91.
Trading performance analysis for GRTS stock
Gritstone bio Inc. [GRTS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -46.08. With this latest performance, GRTS shares dropped by -39.38% in over the last four-week period, additionally sinking by -12.14% over the last 6 months – not to mention a rise of 26.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GRTS stock in for the last two-week period is set at 26.93, with the RSI for the last a single of trading hit 18.82, and the three-weeks RSI is set at 32.56 for Gritstone bio Inc. [GRTS]. The present Moving Average for the last 50 days of trading for this stock 11.56, while it was recorded at 11.54 for the last single week of trading, and 9.83 for the last 200 days.
Gritstone bio Inc. [GRTS]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Gritstone bio Inc. [GRTS] shares currently have an operating margin of -2626.13. Gritstone bio Inc.’s Net Margin is presently recorded at -2608.72.
Return on Total Capital for GRTS is now -60.64, given the latest momentum, and Return on Invested Capital for the company is -61.71. Return on Equity for this stock declined to -69.96, with Return on Assets sitting at -51.88. When it comes to the capital structure of this company, Gritstone bio Inc. [GRTS] has a Total Debt to Total Equity ratio set at 15.05. Additionally, GRTS Total Debt to Total Capital is recorded at 13.08, with Total Debt to Total Assets ending up at 11.33. Long-Term Debt to Equity for the company is recorded at 11.53, with the Long-Term Debt to Total Capital now at 10.02.
Reflecting on the efficiency of the workforce at the company, Gritstone bio Inc. [GRTS] managed to generate an average of -$623,160 per employee. Receivables Turnover for the company is 16.75 with a Total Asset Turnover recorded at a value of 0.02.Gritstone bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.00 and a Current Ratio set at 6.00.
An analysis of insider ownership at Gritstone bio Inc. [GRTS]
There are presently around $517 million, or 62.80% of GRTS stock, in the hands of institutional investors. The top three institutional holders of GRTS stocks are: ECOR1 CAPITAL, LLC with ownership of 5,560,748, which is approximately 62.534% of the company’s market cap and around 0.10% of the total institutional ownership; FRAZIER MANAGEMENT LLC, holding 4,667,242 shares of the stock with an approximate value of $56.89 million in GRTS stocks shares; and AVIDITY PARTNERS MANAGEMENT LP, currently with $54.34 million in GRTS stock with ownership of nearly 110.071% of the company’s market capitalization.
Positions in Gritstone bio Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 48 institutional holders increased their position in Gritstone bio Inc. [NASDAQ:GRTS] by around 12,314,726 shares. Additionally, 51 investors decreased positions by around 4,690,458 shares, while 14 investors held positions by with 25,425,233 shares. The mentioned changes placed institutional holdings at 42,430,417 shares, according to the latest SEC report filing. GRTS stock had 13 new institutional investments in for a total of 485,927 shares, while 21 institutional investors sold positions of 2,176,760 shares during the same period.